Multi-cancer early detection test

The earlier that cancer can be found, the higher the chance of successful treatment and survival. Yet, too often cancer goes undetected until it has progressed to an advanced stage.

In studies, the Galleri test has shown the ability to detect multiple cancers through a simple blood draw. Most of these cancers cannot be detected through current screening paradigms. When cancer was detected, the Galleri test localized the cancer signal with high accuracy, helping inform next steps to diagnosis.1

The Galleri test is not yet commercially available and is currently available only to participants of GRAIL’s clinical studies. The Galleri test is intended to be complementary to, and not a replacement of, U.S. guideline-recommended cancer screening.

CAUTION — Investigational device. Limited by United States law to investigational use. Galleri is a trademark of GRAIL, Inc.
1. Liu MC, et al. Ann Oncol. 2020; 31(6):745-759. DOI:10.1016/j.annonc.2020.02.011